Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer

June 6, 2017

This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.

In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses results of E1305, a phase III randomized trial that tested chemotherapy with or without bevacizumab in patients with recurrent or metastatic squamous cell head and neck cancer.

Burtness presented results of the study (abstract 6000) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.